LIVZON PHARMA (01513): The application for the market approval of Leconqitumab Injection has been accepted by the National Medical Products Administration.
China National Medicines Corporation announced that its controlling subsidiary, Zhuhai Lizhu Monoclonal Antibody Biotechnology Co., Ltd. ("Lizhu Monoclonal Antibody"), has received the "Acceptance Notice" (Acceptance Number: CXSS2500144) issued by the National Medical Products Administration. The application for the domestic production and marketing registration of the Lekangqita Monoclonal Antibody Injection developed jointly by Lizhu Monoclonal Antibody and Beijing Xinkanghe Biotechnology Co., Ltd. has been accepted by the National Medical Products Administration.
Livzon Pharma (01513) announced that its holding subsidiary, Zhuhai Li Zhu Monoclonal Antibody Biotechnology Co., Ltd. (Li Zhu Monoclonal Antibody), has received the "Acceptance Letter" (Acceptance No.: CXSS2500144) issued by the National Medical Products Administration. The application for the registration and listing of the Leconquit Monoclonal Antibody Injection developed jointly by Li Zhu Monoclonal Antibody and Beijing Xin Kanghe Biopharmaceutical Technology Co., Ltd. has been accepted by the National Medical Products Administration for domestic production.
Related Articles
Henan Qingshuiyuan Technology (300437.SZ) plans to transfer the equity of its wholly-owned subsidiary Siweida Company.
Guangzhou Automobile Group (02238): Zheng Heng resigns from the position of deputy general manager.
Fujian Supertech Advanced Material (688398.SH) controlling shareholder plans to reduce its shareholding by no more than 3%.
Henan Qingshuiyuan Technology (300437.SZ) plans to transfer the equity of its wholly-owned subsidiary Siweida Company.
Guangzhou Automobile Group (02238): Zheng Heng resigns from the position of deputy general manager.
Fujian Supertech Advanced Material (688398.SH) controlling shareholder plans to reduce its shareholding by no more than 3%.
RECOMMEND
